|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that GPC3 stimulates the Wnt/β-catenin pathway and mediates the oncogenic function of SULF2 in HCC.
|
20725905 |
2010 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Inversely, the high frequency of β-catenin mutations could be related to the increased frequency of malignant transformation in hepatocellular carcinoma.
|
23046672 |
2013 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
We show that in HCC but not in peritumoral tissue of the same HCC patients, Ln-5, Snail, and Slug are up-regulated, E-cadherin is down-regulated and beta-catenin is translocated into the nuclei.
|
16285938 |
2005 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The results show a modest correlation between diffuse glutamine synthetase immunostaining and exon 3 β-catenin mutations in hepatocellular adenoma and hepatocellular carcinoma with discrepancy rates >50% in both hepatocellular adenoma and hepatocellular carcinoma.
|
27469330 |
2016 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Therefore, our study reveals the evolving nature of β-catenin in HCC to establish it as a compound tumor promoter during the progression of the disease.
|
31015417 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
MiR-655-3p might functions as a tumor suppressor by directly targeting ADAM10 and indirectly regulating β-catenin pathway in the development of progression of HCC.
|
27259866 |
2016 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
These findings unraveled a novel mechanism of c-Myc and Wnt/β-catenin interplay that dictates HCC pathogenesis, and have implications for the potential applicability of miRNA delivery in targeting the newly identified signaling axis and treating metastatic HCCs.
|
29653269 |
2018 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Finally, significant therapeutic benefit of β-catenin knock-down was demonstrated in established HCC tumor xenografts using doxycycline-inducible shRNA system.
|
29383099 |
2017 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
These data identified FXR as a negative regulator of HCC development through direct suppression of Wnt/β-catenin pathway.
|
25650661 |
2015 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of CTNNB1 and MMP9 decreased by knocked down XRCC5 which may promote the progression of HCC via the Wnt/β-catenin signaling pathway.
|
31599408 |
2019 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Moreover, exogenous sFRP1 caused significant decrease of β-catenin/T-cell factor-dependent transcription activity.These findings demonstrate that sFRP1 silencing due to promoter hypermethylation is a major event during tumorigenesis. sFRP1 is also a negative modulator of canonical Wnt signaling, which could contribute to metastasis in HCC progression, thus providing a possible therapeutic strategy against HCC.
|
22296502 |
2012 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
CTNNB1 (40%) and TP53 (21%) mutations were mutually exclusive and defined two major groups of HCC characterized by distinct phenotypes.
|
28532995 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The activation of the Wnt pathway due to β-catenin gene mutations contributes to the development of a significant subset of HCC.
|
21093092 |
2011 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of Cyr61 was positively correlated with increased levels of β-catenin in human HCC samples.
|
22540002 |
2012 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
PRRl1 mRNA expression was found positively correlated with β-catenin (R = 0.5472, P ˂ 0.0001), c-myc (R = 0.5527, P ˂ 0.0001) and cyclinD1 (R = 0.3948, P = 0.0003) in HCC tissues.
|
30248355 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Some driver genes are significantly linked to HCC gender (<i>CTNNB1, ALB, TP53</i>, and <i>AXIN1</i>), race (<i>TP53</i> and <i>CDKN2A</i>), and age (<i>RB1</i>) disparities.
|
30242023 |
2019 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
The frequency of positivity for β-catenin and GS staining was significantly higher in L-FABP-negative cases of small HCC than in L-FABP-positive cases of small HCC (P = 0.009 and P = 0.000, respectively).
|
25516669 |
2014 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In summary, our study demonstrated that TXNDC12 could activate β-catenin via protein-protein interaction and promote ZEB1-mediated EMT and HCC metastasis.
|
31570854 |
2020 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The polymorphism rs4135385 of CTNNB1 genotype GA was associated with a higher risk for Stage III + IV HCC (modified Union for International Cancer Control) (P = 0.001, OR = 2.238).Genetic polymorphisms in the WNT2 and CTNNB1 genes were closely associated with HCC risk and progression in a Chinese Han population.
|
28328801 |
2017 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
LHGDN |
Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
|
18313840 |
2008 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Thus alterations in the beta-catenin gene frequently are selected for during liver tumorigenesis and suggest that disregulation of the Wnt-beta-catenin pathway is a major event in the development of HCC in humans and mice.
|
9671767 |
1998 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Activation of the Wnt signaling pathway is frequently observed in hepatocellular carcinoma (HCC), though mutation of three of its components, CTNNB1, AXIN1, and AXIN2, is observed substantially less often.
|
18592156 |
2008 |
|
Liver carcinoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
In the present study, we identified leupaxin, an adaptor protein sharing homology with the focal adhesion protein, as a novel coactivator for β-catenin in human hepatocellular carcinoma (HCC).
|
26361959 |
2016 |
|
Liver carcinoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Clinicopathological parameters, progression-free survival (PFS) and overall survival (OS) were evaluated to analyze the association of β-catenin expression with prognosis for HCC patients after TACE.
|
30842141 |
2019 |
|
Liver carcinoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The present results indicate that (1) mutation of exon 3 of the beta-catenin gene can lead to beta-catenin accumulation, although other mechanisms of accumulation may also operate in HCC, and (2) beta-catenin accumulation and mutation of the beta-catenin gene are not early events in hepatocarcinogenesis, and may be associated with the malignant progression of HCC.
|
10665646 |
1999 |